Grants and Fundings

ACTIVE  

  • NIH R01     HL139963     (Ishikawa)            12/15/2017 – 11/30/2022          Percutaneous Left Ventricular Unloading for Cardiogenic Shock: Beyond Acute Hemodynamic Support      Role (PI)
  • NIH/NHLBI   1R01HL130423-01 (Ishikawa/Kovacic)         01/25/2016 – 12/31/2021         Toward Therapeutic Manipulation of Endothelial to Mesenchymal Transition.          Role (Co-PI)
  • Abiomed   Inc.        (Ishikawa)                             03/01/2016 – 12/31/2022       Improving the gene transduction efficacy of intracoronary delivery using an Impella     Role (PI)
  • NIH/NHLBI  1R01HL135093 (Fish/Kovacic)    12/01/2016 – 11/30/2021           Therapeutic Mechanisms of Cardiac Progenitors in Ischemic Cardiomyopathy       Role (Co-I)
  • NIH       R01HL148786 (Sahoo)                             07/01/2019 – 06/30/2024             AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery   Role (Co-I)
  • NIH NHLBI GTRP RSA 2035   (Ishikawa)                                                                       Preclinical Vector Production “Improving Cardiac AAV Gene Transduction
    Using Intracoronary Delivery” (PI)

 

  • T32 Research Fellowship (Mazurek)                  09/22/2020 – 09/21/2021
  • ACURE Research Scholar Grant (Mazurek)

Completed

  • AHA-SDG      17SDG33410873     (Ishikawa)    01/01/2017 – 12/31/2019            Mechanistic and Therapeutic Roles of miRNAs in Left Ventricular Remodeling and Heart Failure        Role (PI)
  • NIH       R01HL131404 (Hajjar/Weber)               07/01/2016 – 06/30/2020          Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy       Role (Co-I)
  • Cardiac RSK3 Inhibitors, LLC (Fish)                    02/06/2019 – 02/05/2020         Gene Therapy for Cardiac Remodeling